BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32830792)

  • 1. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
    Zhong J; Zhang J; Yu X; Zhang X; Dian L
    Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line.
    Cao YX; Wen F; Luo ZY; Long XX; Luo C; Liao P; Li JJ
    J Cell Biochem; 2020 Oct; 121(10):4022-4033. PubMed ID: 31793054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
    Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
    J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
    Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
    Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis.
    Wang W; Niu S; Qiao L; Wei F; Yin J; Wang S; Ouyang Y; Chen D
    Biomed Res Int; 2019; 2019():8727935. PubMed ID: 30886864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
    Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
    Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
    Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
    J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling.
    Yu J; Chen WX; Xie WJ; Chen RW; Lin DQ; You WW; Ye WL; Zhang HQ; Lin DH; Xu JP
    J Clin Lab Anal; 2021 Aug; 35(8):e23817. PubMed ID: 34114685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors].
    Shan XY; Chen BA; Xia GH; Xu WL; Ding JH; Gao C; Sun YY; Wang J; Cheng J; Zhao G; Bao W; Song HH; Gao F; Wang F; Wang XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):90-5. PubMed ID: 20137125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
    Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
    Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
    Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
    Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1.
    Yi YJ; Jia XH; Wang JY; Li YJ; Wang H; Xie SY
    Int J Mol Med; 2016 May; 37(5):1405-11. PubMed ID: 27035504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
    Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
    Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.